Skye Bioscience (SKYE) News Today $2.66 -0.04 (-1.48%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Skye Bioscience (NASDAQ:SKYE) Shares Down 2.5% - Here's WhyJanuary 16, 2025 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Shares Down 2.5% - Time to Sell?Skye Bioscience (NASDAQ:SKYE) Stock Price Down 2.5% - Time to Sell?January 16, 2025 | marketbeat.comSkye Bioscience Provides 2025 Look Ahead and Year in ReviewJanuary 13, 2025 | finance.yahoo.com3 trial readouts that could shake up the obesity market this yearJanuary 8, 2025 | finance.yahoo.comSkye Bioscience (NASDAQ:SKYE) Shares Down 3% - Should You Sell?Skye Bioscience (NASDAQ:SKYE) Shares Down 3% - What's Next?December 26, 2024 | marketbeat.comSkye Bioscience to Present at J.P. Morgan Healthcare ConferenceDecember 19, 2024 | globenewswire.comPiper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE)December 16, 2024 | markets.businessinsider.comSkye Bioscience, Inc. (NASDAQ:SKYE) Sees Significant Drop in Short InterestSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,590,000 shares, a decrease of 20.1% from the November 15th total of 1,990,000 shares. Based on an average daily trading volume, of 332,600 shares, the short-interest ratio is presently 4.8 days. Approximately 9.1% of the shares of the company are sold short.December 16, 2024 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Buy" from AnalystsShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price amDecember 14, 2024 | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Skye Bioscience, Inc. (NASDAQ:SKYE)Point72 Asset Management L.P. cut its stake in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 416,424 shares of the company's stock after selling 143,576 sharesDecember 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $1.63 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE)Point72 Asset Management L.P. decreased its stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 416,424 shares of the company's stock afterDecember 11, 2024 | marketbeat.comSkye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative BuyDecember 10, 2024 | seekingalpha.comSkye Bioscience (NASDAQ:SKYE) Trading Down 12.7% - Time to Sell?Skye Bioscience (NASDAQ:SKYE) Trading Down 12.7% - What's Next?December 5, 2024 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Stock Position Lifted by Baker BROS. Advisors LPBaker BROS. Advisors LP raised its stake in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 186.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,434,634 shares of the company's stock after buying an additional 934,634 shares durinDecember 2, 2024 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Shares Acquired by Baker BROS. Advisors LPBaker BROS. Advisors LP increased its position in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 186.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,434,634 shares of the company's stockDecember 2, 2024 | marketbeat.comShort Interest in Skye Bioscience, Inc. (NASDAQ:SKYE) Grows By 26.8%Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,990,000 shares, a growth of 26.8% from the October 31st total of 1,570,000 shares. Based on an average daily volume of 314,400 shares, the days-to-cover ratio is presently 6.3 days. Currently, 11.3% of the company's shares are short sold.December 2, 2024 | marketbeat.comTuan Tu Diep Sells 19,489 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) StockNovember 20, 2024 | insidertrades.comSkye Bioscience, Inc. (NASDAQ:SKYE) CFO Kaitlyn Arsenault Sells 43,206 SharesNovember 19, 2024 | insidertrades.comSkye Bioscience to Participate in Upcoming December Healthcare Investment ConferencesNovember 19, 2024 | markets.businessinsider.comSkye Bioscience, Inc.: Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 InhibitorNovember 14, 2024 | finanznachrichten.deSkye Bioscience achieved more than 50% targeted patient enrollment in CBeyondNovember 14, 2024 | markets.businessinsider.comSkye Bioscience (SKYE) Has a New Rating from Craig-HallumNovember 14, 2024 | markets.businessinsider.comSkye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 InhibitorNovember 14, 2024 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Stock Price Down 1.5% - Should You Sell?Skye Bioscience (NASDAQ:SKYE) Trading Down 1.5% - Time to Sell?November 14, 2024 | marketbeat.comOppenheimer Remains a Buy on Skye Bioscience (SKYE)November 9, 2024 | markets.businessinsider.comSkye Bioscience, Inc. (PNK:SKYE) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comSkye Bioscience Reports Progress in Obesity Drug TrialsNovember 8, 2024 | markets.businessinsider.comSkye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comSkye Bioscience Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comSkye Bioscience Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 7, 2024 | globenewswire.comSkye Bioscience (SKYE) Gets a Buy from ScotiabankNovember 6, 2024 | markets.businessinsider.comSkye Bioscience (SKYE) Scheduled to Post Earnings on ThursdaySkye Bioscience (NASDAQ:SKYE) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643772)November 6, 2024 | marketbeat.comSkye Bioscience announces preliminary data from diet-induced obesity modelNovember 5, 2024 | markets.businessinsider.comSkye Bioscience (SKYE) Receives a Buy from Craig-HallumNovember 5, 2024 | markets.businessinsider.comSkye Bioscience (SKYE) Set to Announce Quarterly Earnings on ThursdaySkye Bioscience (NASDAQ:SKYE) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comSkye Bioscience to Announce Third Quarter 2024 ResultsNovember 1, 2024 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Short Interest UpdateSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,420,000 shares, a growth of 17.4% from the September 30th total of 1,210,000 shares. Approximately 7.8% of the company's shares are sold short. Based on an average daily volume of 325,000 shares, the short-interest ratio is currently 4.4 days.October 30, 2024 | marketbeat.comSkye Bioscience Appoints New Chairman for Strategic GrowthOctober 30, 2024 | markets.businessinsider.comSkye Bioscience names Grayson as Chairman of the BoardOctober 29, 2024 | markets.businessinsider.comSkye Bioscience Names Independent Director Paul Grayson as Chairman of the BoardOctober 29, 2024 | markets.businessinsider.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by BrokeragesSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objectivOctober 25, 2024 | marketbeat.comSkye Bioscience Approves Incentive Plan Amendments and Leadership ChangesOctober 25, 2024 | markets.businessinsider.comSkye Bioscience (NASDAQ:SKYE) Shares Up 5.3% - Still a Buy?Skye Bioscience (NASDAQ:SKYE) Stock Price Up 5.3% - Still a Buy?October 24, 2024 | marketbeat.comSkye Bioscience to Participate in Upcoming November Healthcare Investment ConferencesOctober 21, 2024 | globenewswire.comMarketBeat Week in Review – 10/7 - 10/11 (SKYE)Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earningsOctober 12, 2024 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comDon't Sleep on Skye Bioscience—This Weight Loss Drug Could SoarOctober 10, 2024 | benzinga.comLeo MillerOctober 9, 2024 | entrepreneur.comDon't Sleep on Skye Bioscience-This Weight Loss Drug Could SoarOctober 9, 2024 | msn.comDon’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.October 9, 2024 | marketbeat.com Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Media Mentions By Week SKYE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼0.470.48▲Average Medical News Sentiment SKYE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼23▲SKYE Articles Average Week Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PGEN News TNGX News CMRX News SNDL News BTMD News TRVI News LFVN News VYGR News ITOS News IMMP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
